Clearside Biomedical, Inc. (CLSD) Stock Analysis

Clearside Biomedical, Inc. (CLSD) Healthcare & Pipeline Overview

Clearside Biomedical, Inc. specializes in innovative drug delivery to the back of the eye, primarily through its suprachoroidal space injection platform. With XIPERE approved for uveitic macular edema and a pipeline targeting diabetic macular edema and macular degeneration, Clearside is carving a niche in the competitive biotechnology sector.

What Is the Investment Thesis for CLSD?

Clearside Biomedical presents a focused investment opportunity within the ophthalmology space, driven by its innovative suprachoroidal space (SCS) drug delivery platform. The company's approved product, XIPERE, for uveitic macular edema, provides a revenue stream and validates the SCS approach. Key value drivers include the successful clinical development and commercialization of CLS-AX and CLS-301, targeting larger market opportunities like diabetic macular edema and macular degeneration. The company's collaborations with Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences also represent potential revenue streams and platform validation. However, the company's negative profit margin of -780.9% and reliance on clinical trial outcomes pose significant risks. Upcoming clinical trial results for CLS-AX and CLS-301 will be critical catalysts, while potential delays or failures in these trials represent key risks.

Based on FMP financials and quantitative analysis

CLSD Key Highlights

XIPERE is approved for the treatment of uveitic macular edema, providing an established revenue stream.

• Gross margin of 85.6% indicates strong pricing power for XIPERE.
• CLS-AX is in Phase 1/2a clinical trial, targeting retinal diseases.
• CLS-301 is being developed for diabetic macular edema and macular degeneration, large market opportunities.
• Collaborations with Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences validate the SCS delivery platform.

Who Are CLSD's Competitors?

CLSD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLSD's Key Strengths?

Innovative suprachoroidal space (SCS) drug delivery platform.

• Approved product (XIPERE) for uveitic macular edema.
• Strong gross margin on XIPERE sales.
• Experienced management team.

What Are CLSD's Weaknesses?

Negative profit margin.

• Reliance on clinical trial outcomes.
• Limited product portfolio.
• Small employee base.

What Could Drive CLSD Stock Higher?

CLSD catalyst: Clinical trial results for CLS-AX (axitinib injectable suspension) in Phase 1/2a clinical trial for retinal diseases.

• Clinical trial results for CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration.
• Expansion of XIPERE label to include other indications beyond uveitic macular edema.
• Strategic partnerships with pharmaceutical companies to expand the reach of Clearside's technology.

What Are the Key Risks for CLSD?

Financial-distress signal — its Altman Z-Score of -48.27 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for CLS-AX and CLS-301.
• Competition from established pharmaceutical companies with greater resources.
• Regulatory hurdles and delays in obtaining approvals for new therapies.
• Dependence on the commercial success of XIPERE.
• Negative profit margin and need for additional financing.

What Are the Growth Opportunities for CLSD?

• Expansion of XIPERE Label: Clearside has the opportunity to expand the label for XIPERE to include other indications beyond uveitic macular edema. This would involve conducting additional clinical trials to demonstrate efficacy and safety in new patient populations. The market for macular edema associated with other conditions, such as retinal vein occlusion, represents a significant growth opportunity, potentially increasing XIPERE's market reach and revenue.
• Advancement of CLS-AX: CLS-AX, an axitinib injectable suspension, is currently in Phase 1/2a clinical trial for retinal diseases. Positive results from this trial could pave the way for further clinical development and eventual commercialization. Axitinib is a VEGF inhibitor, a proven mechanism for treating retinal diseases. Successful development of CLS-AX could provide Clearside with a second commercial product targeting a broader range of retinal conditions.
• Development of CLS-301: CLS-301, an integrin inhibitor suspension, is being developed for the treatment of diabetic macular edema and macular degeneration. These are large and growing markets with significant unmet needs. Successful development of CLS-301 could position Clearside as a major player in the treatment of these diseases. The integrin inhibition mechanism offers a novel approach to addressing the underlying pathology of these conditions.
• Strategic Partnerships: Clearside has established collaborations with companies like Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences. These partnerships provide opportunities for revenue generation, platform validation, and expansion into new markets. Further strategic partnerships with other pharmaceutical and biotechnology companies could accelerate the development and commercialization of Clearside's SCS delivery platform and pipeline products.
• Geographic Expansion: Clearside has the opportunity to expand its geographic reach beyond the United States. Partnering with companies that have established distribution networks in other regions, such as Europe and Asia, could accelerate the commercialization of XIPERE and other pipeline products. The global market for ophthalmic therapies is substantial, and geographic expansion represents a significant growth opportunity for Clearside.

What Are CLSD's Competitive Advantages?

• Proprietary suprachoroidal space (SCS) injection platform.
• Approved product (XIPERE) for uveitic macular edema.
• Pipeline of SCS-delivered therapies targeting large markets.
• Established collaborations with pharmaceutical companies.

What Does CLSD Do?

Clearside Biomedical, Inc., founded in 2011 and headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing and delivering therapies to the back of the eye. The company's core technology revolves around accessing the suprachoroidal space (SCS), a space located between the sclera and the choroid, to deliver drugs directly to the retina and other posterior structures of the eye. This targeted approach aims to improve drug efficacy and reduce systemic side effects compared to traditional methods. Clearside's lead product, XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), is approved for the treatment of uveitic macular edema. Beyond XIPERE, Clearside is advancing a pipeline of SCS-delivered therapies, including CLS-AX (axitinib injectable suspension) in Phase 1/2a clinical trial for retinal diseases and CLS-301, an integrin inhibitor suspension for diabetic macular edema and macular degeneration. Clearside has established collaborations with companies like Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences to expand the reach and application of its SCS delivery platform.

What Products and Services Does CLSD Offer?

• Develops therapies for the back of the eye.
• Utilizes a suprachoroidal space (SCS) injection platform for targeted drug delivery.
• Offers XIPERE for the treatment of uveitic macular edema.
• Develops CLS-AX for retinal diseases.
• Develops CLS-301 for diabetic macular edema and macular degeneration.
• Collaborates with pharmaceutical companies to expand the reach of its technology.

How Does CLSD Make Money?

• Develops and commercializes ophthalmic therapies.
• Generates revenue from sales of XIPERE.
• Out-licenses its SCS delivery platform to other companies.
• Receives milestone payments and royalties from collaborations.

What Industry Does CLSD Operate In?

Clearside Biomedical operates in the competitive biotechnology industry, specifically within the ophthalmology segment. The market for treatments targeting retinal diseases, such as diabetic macular edema and macular degeneration, is substantial and growing, driven by an aging population and increasing prevalence of diabetes. Clearside's suprachoroidal space (SCS) delivery platform offers a differentiated approach compared to traditional intravitreal injections, potentially improving drug efficacy and reducing side effects. The company competes with established pharmaceutical companies and other biotechnology firms developing novel therapies for eye diseases. Success in this market depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Who Are CLSD's Key Customers?

• Patients with uveitic macular edema.
• Ophthalmologists and retinal specialists.
• Hospitals and clinics.
• Pharmaceutical companies through collaborations.

Company Profile

Clearside Biomedical, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alpharetta, US. The company is led by CEO George Lasezkay. CLSD has traded publicly since 2016.

Clearside Biomedical, Inc. Financial Trajectory

Clearside Biomedical, Inc. (CLSD) reported $201K in revenue for Sep 2025, a decline of 59.1% compared to the prior quarter. The company recorded a net loss of $6.0M, with diluted EPS of $-1.14. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CLSD averaged $-1.26 in diluted EPS.

How Clearside Biomedical, Inc. Is Valued

Clearside Biomedical, Inc. carries a market capitalization of $2.15M, placing it in the micro-cap category.

Return on equity for Clearside Biomedical, Inc. stands at 55.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.98 indicates the company holds enough short-term assets to cover its near-term obligations.

Clearside Biomedical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.27 places it in the distress zone, a signal of elevated financial risk.

Clearside Biomedical, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 647.9% below estimates on average.

Wall Street analysts project Clearside Biomedical, Inc. revenue of about $6.8M for fiscal 2026, with EPS near $-3.30. The estimate reflects 4 contributing analysts.

The most recent 2 insider filings for Clearside Biomedical, Inc. break down as 0 sales and 2 purchases. On net that is roughly 350K shares acquired (about $572K) — insiders putting money in tends to read as conviction.

CLSD Financials

CLSD Latest News

CLSD Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources